QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   316.95 (-0.02%)
META   300.51 (+0.48%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.21 (+0.54%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   316.95 (-0.02%)
META   300.51 (+0.48%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.21 (+0.54%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   316.95 (-0.02%)
META   300.51 (+0.48%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.21 (+0.54%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   316.95 (-0.02%)
META   300.51 (+0.48%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.21 (+0.54%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:VTYX

Ventyx Biosciences (VTYX) Stock Forecast, Price & News

$33.87
-0.66 (-1.91%)
(As of 04:00 PM ET)
Compare
Today's Range
$33.59
▼
$34.64
50-Day Range
$29.80
▼
$37.76
52-Week Range
$23.89
▼
$47.25
Volume
368,979 shs
Average Volume
732,763 shs
Market Capitalization
$1.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.88
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Ventyx Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
71.6% Upside
$57.88 Price Target
Short Interest
Bearish
20.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Ventyx Biosciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$17.78 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.26) to ($3.85) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

741st out of 961 stocks

Pharmaceutical Preparations Industry

346th out of 456 stocks

See Top Rated MarketRank™ Stocks Here

VTYX stock logo

About Ventyx Biosciences (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

VTYX Price History

VTYX Stock News Headlines

September 24, 2023 | americanbankingnews.com
Ventyx Biosciences (NASDAQ:VTYX) Stock Price Down 2.5%
September 24, 2023 | americanbankingnews.com
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Rating of "Buy" from Analysts
September 25, 2023 | Chaikin Analytics (Ad)
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
September 22, 2023 | americanbankingnews.com
Somu Subramaniam Sells 56,665 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock
September 11, 2023 | markets.businessinsider.com
Piper Sandler Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)
September 11, 2023 | finance.yahoo.com
Insider Sell: CFO Martin Auster Sells 26,472 Shares of Ventyx Biosciences Inc
August 20, 2023 | fool.com
Ventyx Biosciences (NASDAQ: VTYX)
August 15, 2023 | finance.yahoo.com
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2023 Earnings Call Transcript
September 25, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
August 14, 2023 | seekingalpha.com
Ventyx: Promising, But Data Will Need To Justify Optimistic Valuation
August 11, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX), Amylyx Pharmaceuticals Inc (AMLX) and Aptose Biosciences (APTO)
August 11, 2023 | markets.businessinsider.com
Where Ventyx Biosciences Stands With Analysts
August 11, 2023 | finanznachrichten.de
Ventyx Biosciences, Inc.: Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress
August 11, 2023 | finance.yahoo.com
Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress
August 3, 2023 | finance.yahoo.com
Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023
August 2, 2023 | finance.yahoo.com
Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference
July 11, 2023 | markets.businessinsider.com
Piper Sandler Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)
July 7, 2023 | seekingalpha.com
Why did Ventyx Biosciences stock drop today? Large shareholder sale
July 7, 2023 | benzinga.com
Director of Ventyx Biosciences Makes $5.23M Sale
July 7, 2023 | benzinga.com
10% Owner of Ventyx Biosciences Sold $5.23M In Stock
July 6, 2023 | benzinga.com
Chief Executive Officer at Ventyx Biosciences Exercises Options Worth $1.08M
July 6, 2023 | benzinga.com
Chief Business Officer at Ventyx Biosciences Exercises Options Worth $546K
July 5, 2023 | markets.businessinsider.com
Analyst Ratings for Ventyx Biosciences
July 5, 2023 | markets.businessinsider.com
LifeSci Capital Remains a Buy on Ventyx Biosciences (VTYX)
July 5, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Ventyx Biosciences (VTYX), Avadel Pharmaceuticals (AVDL)
July 3, 2023 | finance.yahoo.com
Why Shares of Ventyx Biosciences Rose Monday
June 15, 2023 | seekingalpha.com
Ventyx: Critical Proof Of Concept Data Later This Year
See More Headlines
Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

VTYX Company Calendar

Last Earnings
8/10/2023
Today
9/25/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTYX
CUSIP
N/A
CIK
1851194
Web
www.ventyxbio.com
Phone
760-593-4832
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$57.88
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$46.00
Forecasted Upside/Downside
+69.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-108,430,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-43.67%
Return on Assets
-41.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
17.31
Quick Ratio
17.31

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.25 per share
Price / Book
5.47

Miscellaneous

Outstanding Shares
58,710,000
Free Float
44,391,000
Market Cap
$2.01 billion
Optionable
Not Optionable
Beta
-0.36
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Sheila K. Gujrathi M.D. (Age 53)
    Exec. Chairperson
    Comp: $125k
  • Dr. Raju S. Mohan Ph.D. (Age 65)
    Founder, CEO & Director
    Comp: $989.99k
  • Dr. William J. Sandborn M.D. (Age 60)
    Ph.D., Pres & Chief Medical Officer
    Comp: $872.26k
  • Dr. John M. Nuss Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $656.99k
  • Dr. Martin Douglas Auster M.D. (Age 48)
    Chief Financial Officer
  • Mr. Christopher W. Krueger J.D. (Age 55)
    MBA, Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VTYX Stock - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VTYX shares.
View VTYX analyst ratings or view top-rated stocks.

What is Ventyx Biosciences' stock price forecast for 2023?

7 Wall Street research analysts have issued twelve-month price objectives for Ventyx Biosciences' shares. Their VTYX share price forecasts range from $46.00 to $77.00. On average, they predict the company's share price to reach $57.88 in the next year. This suggests a possible upside of 69.3% from the stock's current price.
View analysts price targets for VTYX or view top-rated stocks among Wall Street analysts.

How have VTYX shares performed in 2023?

Ventyx Biosciences' stock was trading at $32.79 at the start of the year. Since then, VTYX shares have increased by 4.2% and is now trading at $34.18.
View the best growth stocks for 2023 here.

When is Ventyx Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our VTYX earnings forecast.

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) issued its earnings results on Thursday, August, 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.20. During the same quarter last year, the firm posted ($0.39) earnings per share.

What ETFs hold Ventyx Biosciences' stock?

ETFs with the largest weight of Ventyx Biosciences (NASDAQ:VTYX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL), Alger Mid Cap 40 ETF (FRTY), ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).iShares U.S. Pharmaceuticals ETF (IHE).

When did Ventyx Biosciences IPO?

(VTYX) raised $152 million in an IPO on Thursday, October 21st 2021. The company issued 9,472,656 shares at $15.00-$17.00 per share.

What is Ventyx Biosciences' stock symbol?

Ventyx Biosciences trades on the NASDAQ under the ticker symbol "VTYX."

Who are Ventyx Biosciences' major shareholders?

Ventyx Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.99%), Capital International Investors (5.07%), Goldman Sachs Group Inc. (2.66%), Holocene Advisors LP (2.61%), State Street Corp (1.77%) and Driehaus Capital Management LLC (1.64%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White.
View institutional ownership trends.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ventyx Biosciences' stock price today?

One share of VTYX stock can currently be purchased for approximately $34.18.

How much money does Ventyx Biosciences make?

Ventyx Biosciences (NASDAQ:VTYX) has a market capitalization of $2.01 billion. The company earns $-108,430,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

How can I contact Ventyx Biosciences?

The official website for the company is www.ventyxbio.com. The company can be reached via phone at 760-593-4832 or via email at ir@ventyxbio.com.

This page (NASDAQ:VTYX) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -